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Background 
Although clopidogrel (CLO) pretreatment benefits PCI patients with acute coronary syndromes, these 
benefits are less well-established among elective PCI patients—particularly when treated with the 
direct thrombin inhibitor (DTI), bivalirudin. The effect of timing of CLO pretreatment on ischemic 
complications in these patients is also unknown. 
 
Methods 
We used data from the multicenter EVENT registry to assess the association of clopidogrel 
pretreatment (600 mg 2 hr pre-PCI, 300 mg 6 hrs pre-PCI, or 75 mg/d for 1 week) with PCI-related 
complications in patients undergoing elective PCI with a DTI as planned antithrombotic. The primary 
endpoint was the composite of in-hospital death or MI (peak CKMB > 3 x ULN).   
 
Results 
Between 01/05 and 12/07, 3568 pts underwent elective PCI and 1913 (54%) received DTI as planned 
anticoagulant (37% diabetics, age 65±10 y). Clopidogrel pre-treatment was used in 923 (48%). There 
were no differences in in-hospital or 1 year ischemic or bleeding events in relation to clopidogrel 
pretreatment in both unadjusted and adjusted analyses (see Table). There was a trend toward lower 
rates of death or MI with earlier pretreatment, however [Odds ratios vs. no pretreatment: >1 week 0.48 
(95% CI 0.08 - 2.73); > 6 h OR 0.69 (95% CI 0.11 - 4.45) and 2-6 h OR 0.77 (95% CI 0.18 - 3.31)]. 
 
Conclusion 
Among unselected patients undergoing elective PCI with DTI as the planned anticoagulant, 
clopidogrel pretreatment was common, but was not associated with a reduced risk of ischemic 
complications.  
 
